These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18241932)

  • 1. Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora.
    Repa A; Kozakova H; Hudcovic T; Stepankova R; Hrncir T; Tlaskalova-Hogenova H; Pollak A; Wiedermann U
    Immunol Lett; 2008 Apr; 117(1):50-6. PubMed ID: 18241932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
    Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy.
    Wiedermann U; Jahn-Schmid B; Bohle B; Repa A; Renz H; Kraft D; Ebner C
    J Allergy Clin Immunol; 1999 Jun; 103(6):1202-10. PubMed ID: 10359907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy.
    Repa A; Wild C; Hufnagl K; Winkler B; Bohle B; Pollak A; Wiedermann U
    Clin Exp Immunol; 2004 Jul; 137(1):12-8. PubMed ID: 15196238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bystander suppression to unrelated allergen sensitization through intranasal administration of tolerogenic exosomes in mouse.
    Prado N; Cañamero M; Villalba M; Rodríguez R; Batanero E
    Mol Immunol; 2010 Jul; 47(11-12):2148-51. PubMed ID: 20478618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities.
    Wild C; Wallner M; Hufnagl K; Fuchs H; Hoffmann-Sommergruber K; Breiteneder H; Scheiner O; Ferreira F; Wiedermann U
    Allergy; 2007 Jan; 62(1):33-41. PubMed ID: 17156339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen.
    Marazuela EG; Rodríguez R; Fernández-García H; García MS; Villalba M; Batanero E
    Mol Immunol; 2008 Jan; 45(2):438-45. PubMed ID: 17662454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal colonization of germ-free mice with Bifidobacterium longum prevents allergic sensitization to major birch pollen allergen Bet v 1.
    Schwarzer M; Srutkova D; Schabussova I; Hudcovic T; Akgün J; Wiedermann U; Kozakova H
    Vaccine; 2013 Nov; 31(46):5405-12. PubMed ID: 24055352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.
    Winkler B; Hufnagl K; Spittler A; Ploder M; Kállay E; Vrtala S; Valenta R; Kundi M; Renz H; Wiedermann U
    Allergy; 2006 Feb; 61(2):173-80. PubMed ID: 16409192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy.
    Wiedermann U; Jahn-Schmid B; Repa A; Kraft D; Ebner C
    Int Arch Allergy Immunol; 1999; 118(2-4):129-32. PubMed ID: 10224359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
    Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
    Int Immunol; 1999 Jul; 11(7):1131-8. PubMed ID: 10383946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
    Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
    J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides.
    Hufnagl K; Focke M; Gruber F; Hufnagl P; Loupal G; Scheiner O; Wiedermann U
    Clin Exp Allergy; 2008 Jul; 38(7):1192-202. PubMed ID: 18462454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses.
    Bublin M; Hoflehner E; Wagner B; Radauer C; Wagner S; Hufnagl K; Allwardt D; Kundi M; Scheiner O; Wiedermann U; Breiteneder H
    Vaccine; 2007 Dec; 25(50):8395-404. PubMed ID: 17997199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice.
    Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U
    PLoS One; 2012; 7(6):e39409. PubMed ID: 22768077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.
    Winkler B; Baier K; Wagner S; Repa A; Eichler HG; Scheiner O; Kraft D; Wiedermann U
    Clin Exp Allergy; 2002 Jan; 32(1):30-6. PubMed ID: 12002733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1.
    Kitzmüller C; Nagl B; Deifl S; Walterskirchen C; Jahn-Schmid B; Zlabinger GJ; Bohle B
    Allergy; 2012 May; 67(5):593-600. PubMed ID: 22188598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis.
    Keen C; Johansson S; Reinholdt J; Benson M; Wennergren G
    Pediatr Allergy Immunol; 2005 May; 16(3):209-16. PubMed ID: 15853949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy.
    Wiedermann U; Jahn-Schmid B; Lindblad M; Rask C; Holmgren J; Kraft D; Ebner C
    Int Immunol; 1999 Oct; 11(10):1717-24. PubMed ID: 10508191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.